Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Polarean Imaging Plc | LSE:POLX | London | Ordinary Share | GB00BF3DT583 | ORD GBP0.00037 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.05 | 3.28% | 1.575 | 4,349,399 | 09:01:16 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 1.50 | 1.65 | 1.625 | 1.575 | 1.60 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Surgical,med Instr,apparatus | USD 891k | USD -11.89M | USD -0.0098 | -1.60 | 18.41M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 10:27:12 | O | 29,078 | 1.50 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 21/11/2024 | 07:00 | UK RNS | Polarean Imaging PLC FDA clears Chest Coil in GE HealthCare MRI Systems |
| 25/9/2024 | 06:00 | UK RNS | Polarean Imaging PLC Virtual investor day |
| 04/9/2024 | 10:57 | ALNC |  EARNINGS: Gulf Marine backs outlook; Ecora swings to profit |
| 04/9/2024 | 06:00 | UK RNS | Polarean Imaging PLC Half-year Report |
| 03/9/2024 | 06:00 | UK RNS | Polarean Imaging PLC Appointment of Vice President of Sales |
| 28/8/2024 | 17:25 | ALNC | IN BRIEF: Polarean adds "pulmonary expertise" with new medical chief |
| 28/8/2024 | 06:00 | UK RNS | Polarean Imaging PLC Appointment of Chief Medical Advisor |
| 21/8/2024 | 06:00 | UK RNS | Polarean Imaging PLC Notice of Results |
| 15/8/2024 | 06:00 | UK RNS | Polarean Imaging PLC Appointment of Bastiaan Driehuys as consultant |
| 01/8/2024 | 06:00 | UK RNS | Polarean Imaging PLC FDA submission to expand minimum age for XENOVIEW™ |
Polarean Imaging (POLX) Share Charts1 Year Polarean Imaging Chart |
|
1 Month Polarean Imaging Chart |
Intraday Polarean Imaging Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 21/11/2024 | 10:00 | Polarean Imaging PLC | 8,044 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 10:27:12 | 1.50 | 29,078 | 436.17 | O |
| 10:26:51 | 1.57 | 90,000 | 1,408.77 | O |
| 10:22:03 | 1.62 | 100,000 | 1,620.00 | O |
| 10:19:38 | 1.50 | 29 | 0.44 | O |
| 09:35:39 | 1.62 | 30,618 | 496.01 | O |
| Top Posts |
|---|
Posted at 21/11/2024 08:20 by Polarean Imaging Daily Update Polarean Imaging Plc is listed in the Surgical,med Instr,apparatus sector of the London Stock Exchange with ticker POLX. The last closing price for Polarean Imaging was 1.53p.Polarean Imaging currently has 1,207,032,781 shares in issue. The market capitalisation of Polarean Imaging is £18,950,415. Polarean Imaging has a price to earnings ratio (PE ratio) of -1.60. This morning POLX shares opened at 1.60p |
Posted at 15/11/2024 12:34 by moontheloon Polx about to fall back away from 2p on not enough commercialisation news. None in 4 months. Massive wage bill increase. And as the last 4 months since fund raise without news will continue to trade within the margins kept 1.2 to 1.6 average over the last 4 months. Won't get down to placing level, And btw chart wise double tops are never great confirmation patterns and suggest bears are taking over, with resultant fall back of share price. Dyor. |
Posted at 15/11/2024 11:28 by goldbutler Total of $30m to $35m, inclusive of money raised in the anticipated 2024 financing, from investment and strategic deals needed to fund the Company to profitability, investment focused on:Polarean strategic update as above - TWO years since FDA approval - failure to commercialise ONE denovo sale to Alabama and ONE denovo sale to an unnamed !!!! client Directors taking over $1 million cash and nearly the same $1 million cost of options - no cutbacks for von jacko on at least 3/4million cash. 30 staff employed - the most expensive salaries and wages finance department in the USA because few sales invoices. Directors REPRICED their options because the share price fell - same directors Directors allocate themselves over 181 million more options to motivate themselves- not content with million in cash for their fees and salaries Nukem and Bracco and directors with options have taken nearly 50% of the company FAILURE to deliver - Destruction of share price - The stock market doesn't rate them - just look at the graph the directors are looking after themselves Complete refusal to market in partnership into any other jurisdiction including the UK - WHY? |
Posted at 15/11/2024 10:20 by m_night10 You waste your time and life moon. A few buys like the 740k you see now and it will go to 2p and then over with news faster than you can blink. :)POLX Polarean Imaging about to break out well above 2p soon. Mcap only $20mil. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 1.6p and gap at to 3.4p. ATH 100p. Cash runway to minimum of Q1 2026, looks set to be extended given revenues ahead of expectations. Putting this UK recovery play potential on radars. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target imv. DYOR, not advice. |
Posted at 14/11/2024 09:11 by m_night10 POLX Polarean Imaging about to break out well above 2p soon. Mcap only $20mil. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 1.6p and gap at to 3.4p. ATH 100p. Cash runway to minimum of Q1 2026, looks set to be extended given revenues ahead of expectations.Putting this UK recovery play potential on radars. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target imv. DYOR, not advice. |
Posted at 08/11/2024 08:36 by m_night10 POLX Polarean Imaging about to break out above 2p soon. Mcap only $25mil. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 1.65p and gap at over 3p. ATH 100p. Cash runway to minimum of Q1 2026, looks set to be extended given revenues ahead of expectations.Putting this UK recovery play potential on radars. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target imv. DYOR, not advice. |
Posted at 08/11/2024 08:12 by moontheloon As we have known for long before you arrived bones. And as usual it's physical ones we are involved in that will move the price significantly. Once you rampers got another fraction of a penny it will be a rush to the doors. Time is ticking that's another week out of 26 available to get enough deals that would avoid talk starting off another dilution. And resultant share price drift downwards as happened previously. |
Posted at 17/10/2024 15:19 by m_night10 POLX Mcap sub $20MIL right now I see it as a steal for Xenon MRI. No company debt, masssive growth potential, important best in class next generation MRI.1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout |
Posted at 19/7/2024 10:09 by fft Errr. POLX are buying the older machines and selling them the newer ones. There is no mention of how much POLX are paying for them, and I suspect it is higher than the price POLX will get when they try and sell them again !This seems like a loss leader to get influential people involved. Note, there is no quote from the Virginia people saying how they always wanted the POLX kit. Indeed, unless I have looked at a wrong version of the RNS there is no quote at all In other words POLX are probably losing money on this deal and if other sites see this they may also like to do a trade in, but the more that do it the worse for POLX cash flow. My 2 cents |
Posted at 09/7/2024 19:59 by goldbutler The share price graph shows the stock market reaction over the last 2 yearsand the market does not rate this Board Of Directors very highly. The CEO ex Brainsway just has to look at that share price graph not his Linkedin page. Chairman K West is taking every cent and dollar he can lay his hand on from Polarean and he is the Chairman responsible for the shambles since FDA approval. He has achieved almost nothing by way of sales in the last 18 months and the forecast from the company itself is not much better for the next 18 months. Nukem and Bracco have paid so little for the company they and the Board Minus the Director resignations must be delighted. No investormeet, no questions and no answers and UK shareholders can visit america again if the want to vote in a show of hands. |
Posted at 20/6/2024 09:46 by kingston78 I think that the two largest shareholders / backers of the company will, at an opportune time, engineer a bid for POLX by a larger group. They will clobber their shareholdings, together with recommendation by the directors, agree to a sale of the company at an attractive price.Digressing a little, private equity consortium has had their bid offers for Hargreaves Landsdown refused twice. But the directors will agree to a much higher offer of £5.4 billion for HL. The same thing will happen to POLX in my opinion, at 10 p each share when the company has won sufficient number of users for its products. There will be a push for worldwide offering. You just need to look at the historical share chart to see how much the company will claw back in terms of share price. A bid or not, there is a compelling business case for the share price to go higher. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
